精神分裂症的神经炎性反应研究现状

doi:10.3969/j.issn.1006-7795.2019.02.010

首都医科大学学报 ›› 2019, Vol. 40 ›› Issue (2): 205-208.doi: 10.3969/j.issn.1006-7795.2019.02.010

精神分裂症的神经炎性反应研究现状

马超¹, 贾竑晓^1,2

1. 首都医科大学附属北京安定医院中西医结合研究室, 北京 100088;
2. 北京市精神疾病诊断与治疗重点实验室, 北京 100088

收稿日期:2019-01-18 出版日期:2019-03-21 发布日期:2019-04-15
通讯作者: 贾竑晓 E-mail:jhxlj@ccmu.edu.com
基金资助:
国家自然科学基金（81873398），首都卫生发展科研专项重点攻关项目（首发2018-1-2122），北京中医药科技发展基金项目（JJ2018-42）。

Current status of research concerning neuroinflammation schizophrenia

Ma Chao¹, Jia Hongxiao^1,2

1. Chinese Medicine Research Center, Beijing Anding Hospital, Capital Medical University, Beijing 100088, China;
2. Beijing Key Laboratory for Mental Disorders and Treatment, Beijing 100088, China

Received:2019-01-18 Online:2019-03-21 Published:2019-04-15
Supported by:
This study was supported by National Natural Science Foundation of China (81873398),Capital Health Research and Development of Special Founding (2018-1-2122), Beijing Traditional Chinese Medicine Science and Technology Development Foundation(JJ2018-42).

摘要/Abstract

摘要： 精神分裂症是一种常见的精神障碍，目前机制未明。已有多种假说被相继提出，最早于20世纪80年代，有临床研究表明精神分裂症在外周以及脑内存在炎性反应的激活及免疫系统的失调，近些年来抗精神病药和抗炎药物的联合使用改善了精神分裂症患者相关症状，表明神经炎性反应在精神分裂症的发病中起到了一定作用。本文结合近年来研究，综述神经炎性反应对精神分裂症影响的研究现状。

关键词: 精神分裂症, 神经炎性反应, 细胞因子

Abstract: Schizophrenia is a common mental disorder, the mechanism of which remains unknown at present. Many hypotheses have been put forward. As early as the 1980s, three were the clinical studies showing that schizophrenia activated the inflammatory response and the immune system disorders in the peripheral nervous system and the brain. In recent years, psychiatric drugs and anti-inflammatory drugs are used in combination to improve the symptoms in schizophrenic patients, suggesting that nerve inflammation played a role in the onset of schizophrenia. The neuroinflammation effects on schizophrenia are reviewed in this article.

Key words: schizophrenia, neuroinflammation, cytokines

中图分类号:

R749

马超, 贾竑晓. 精神分裂症的神经炎性反应研究现状[J]. 首都医科大学学报, 2019, 40(2): 205-208.

Ma Chao, Jia Hongxiao. Current status of research concerning neuroinflammation schizophrenia[J]. Journal of Capital Medical University, 2019, 40(2): 205-208.

参考文献

[1] Huang Y Q, Wang Y, Wang H, et al. Prevalence of mental disorders in China:a cross-sectional epidemiological study[J]. Lancet Psychiatry, 2019,6(3):211-224.
[2] Gilmour G, Dix S, Fellini L, et al. NMDA receptors, cognition and schizophrenia-testing the validity of the NMDA receptor hypofunction hypothesis[J]. Neuropharmacology, 2012, 62(3):1401-1412.
[3] Mosser C A, Baptista S, Arnoux I, et al. Microglia in CNS development:shaping the brain for the future[J]. Progr Neurobiol, 2017, 149-150:1-20.
[4] Busse M, Bielau H, Müller, et al. Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia:further evidence for disease course-related immune alterations?[J]. Brain Behav Immun, 2012, 26(8):1273-1279.
[5] Mallya A P, Wang H D, Lee H N R, et al. Microglial pruning of synapses in the prefrontal cortex during adolescence[J]. Cereb Cortex, 2019,29(4):1634-1643.
[6] Fuller S, Steele M, Münch G, et al. Activated astroglia during chronic inflammation in alzheimer's disease-do they neglect their neurosupportive roles?[J]. Mutat Res, 2010, 690(1-2):40-49.
[7] Uranova N A, Vikhreva O V, Rachmanova V I, et al. Ultrastructural alterations of myelinated fibers and oligodendrocytes in the prefrontal cortex in schizophrenia:a postmortem morphometric study[J]. Schizophr Res Treatment, 2011, 2011:325789.
[8] Tsai S J. Effects of, interleukin-1beta, polymorphisms on brain function and behavior in healthy and psychiatric disease conditions[J]. Cytokine Growth Factor Rev, 2017,37:89-97.
[9] Yirmiya R, Winocur G, Goshen I. Brain interleukin-1 is involved in spatial memory and passive avoidance conditioning[J]. Neurobiol Learn Mem, 2002, 78(2):379-389.
[10] Ghafelehbashi H, Pathleran Kakhki M, Kular L, et al. Decreased expression of IFNG-AS1, IFNG and IL-1B inflammatory genes in medicated schizophrenia and bipolar patients[J]. Scand J Immunol, 2017, 86(6):479-485.
[11] Boerrigter D, Weickert T W, Lenroot R, et al. Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder[J]. J Neuroinflammation, 2017, 14(1):188-232.
[12] Goldsmith D R, Haroon E, Miller A H, et al. TNF-α and IL-6 are associated with the deficit syndrome and negative symptoms in patients with chronic schizophrenia[J]. Schizophr Res, 2018,199:281-284.
[13] Boin F, Zanardini R, Pioli R, et al. Association between-G308A tumor necrosis factor alpha gene polymorphism and schizophrenia[J]. Mol Psychiatry, 2001, 6(1):79-82.
[14] Stroubini T, Perrea D, Perelas A, et al. Effect of sibutramine on regional fat pads and leptin levels in rats fed with three isocaloric diets[J]. Eur Cytokine Netw, 2008, 19(3):149-155.
[15] Fang X, Zhang Y, Fan W, et al. Interleukin-17 alteration in first-episode psychosis:a Meta-analysis[J]. Mol Neuropsychiatry,2018,3(3):135-140.
[16] Borovcanin M, Jovanovic I, Dejanovic S D, et al. Increase systemic levels of IL-23 as a possible constitutive marker in schizophrenia[J]. Psychoneuroendocrinology, 2015, 56:143-147.
[17] Nora B, Mariam H, Jawad F, et al. Inflammation and elevation of interleukin-12p40 in patients with schizophrenia[J]. Front Mol Neurosci, 2016, 9:16.
[18] Laan W, Grobbee D E, Selten J D, et al. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders:results from a randomized, double-blind, placebo-controlled trial[J]. J Clin Psychiatry, 2010, 71(5):520-527.
[19] Kelly D L, Sullivan K M, McEvoy J P, et al. Adjunctive minocycline in clozapine-treated schizophrenia patients with persistent symptoms[J]. J Clin Psychopharmacol, 2015, 35(4):374-381.
[20] Weiser M, Levi L, Burshtein S, et al. The effect of minocycline on symptoms in schizophrenia:results from a randomized controlled trial[J]. Schizophr Res, 2018, pii:90920-9964(18)30625-X.
[21] 徐园园, 贾竑晓.精神分裂症临床分期模型的研究进展[J].首都医科大学学报,2018,39(2):213-216.

精神分裂症的神经炎性反应研究现状

Current status of research concerning neuroinflammation schizophrenia

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王平, 杨军, 王向东, 张罗. 黄芩苷对脂多糖诱导的人单核细胞THP-1的炎症反应的作用[J]. 首都医科大学学报, 2022, 43(6): 893-898.
[2]	廉思源, 吴涵, 韩金祥, 肖存利, 任艳萍, 金文青, 王雯, 马辛. 影响精神分裂症自我报告康复效果的因素[J]. 首都医科大学学报, 2022, 43(2): 233-238.
[3]	李莉, 刘超猛, 任艳萍, 杨春林, 马辛. 改良电休克治疗首发精神分裂症的研究进展[J]. 首都医科大学学报, 2022, 43(2): 249-253.
[4]	郭城伟, 周娇娇, 冯媛, 杨蕴萍. 精神分裂症患者与正常人自尊水平的对照研究[J]. 首都医科大学学报, 2022, 43(2): 294-298.
[5]	陈溪, 马登磊, 李林. 淫羊藿苷对cuprizone诱导精神分裂症样小鼠模型行为学变化、髓鞘脱失及神经炎性反应的影响[J]. 首都医科大学学报, 2021, 42(5): 761-767.
[6]	宁艳哲, 朱虹, 宋楠, 郑思思, 李自艳, 李佳佳, 马睿, 贾竑晓. 石珍安神颗粒改善精神分裂症前驱期患者认知损害的临床观察[J]. 首都医科大学学报, 2021, 42(3): 404-407.
[7]	王雨晴, 陈志刚, 李芳芳, 张斯佳, 罗玉敏, 赵海苹. 蛋白激酶Pbk在缺氧神经胶质细胞中的变化及与IGF-1的相关性[J]. 首都医科大学学报, 2021, 42(2): 251-256.
[8]	仪玉伟, 闫芳, 靳玉宏, 肖存利. 精神分裂症住院患者危险行为的影响因素分析[J]. 首都医科大学学报, 2021, 42(2): 323-327.
[9]	沙莎, 赵希希, 韩传亮, 彭兴, 张培, 董雯, 尹晶晶, 王长明. 精神分裂症静息态下alpha活动和认知水平的相关性[J]. 首都医科大学学报, 2021, 42(1): 117-124.
[10]	张颖, 王若梅, 李刚. 稳定期精神分裂症患者认知功能、情绪管理水平及其影响因素分析[J]. 首都医科大学学报, 2021, 42(1): 143-147.
[11]	袁惠莉, 宫晓丽, 范征, 梁志刚, 王晓民. 远志皂苷对脂多糖诱导的帕金森病模型大鼠的作用及机制研究[J]. 首都医科大学学报, 2020, 41(6): 914-922.
[12]	施焕中. 专注于胸膜疾病的基础与临床研究——施焕中教授团队[J]. 首都医科大学学报, 2020, 41(5): 736-741.
[13]	刘鑫垚, 马超, 贾竑晓. 精神分裂症认知损害动物模型的研究现状[J]. 首都医科大学学报, 2020, 41(1): 50-54.
[14]	马超, 贺毅, 孙作厘, 刘鑫垚, 冯正田, 陈沛, 宁艳哲, 朱虹, 尹冬青, 贾竑晓. 基于16S rRNA技术分析石珍安神汤对脱髓鞘小鼠肠道菌群多样性的影响[J]. 首都医科大学学报, 2020, 41(1): 64-70.
[15]	何笑笑, 周福春, 王传跃, 朱辉, 及晓, 关鸿志. 精神科急诊紧张症临床特征分析[J]. 首都医科大学学报, 2019, 40(5): 688-692.